News

Gilead to buy Immunomedics for $21bn

Gilead to buy Immunomedics for $21bn

The move adds Trodelvy, a first-in-class antibody-drug conjugate approved to treat triple-negative breast cancer, to the drugmaker’s portfolio

NICE backs Portola’s Ondexxya

NICE backs Portola’s Ondexxya

The drug’s use has, however, been restricted to reversing anticoagulation from apixaban or rivaroxaban in adults with life threatening or uncontrolled bleeding in the gastrointestinal tract